Shopping Cart

Your shopping cart is currently empty

BMS-202

Name: BMS-202
Brand: TargetMol
SKU: T3146
Price: 41 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: PD1-PDL1 inhibitor 2, PD-1/PD-L1 inhibitor 2) Copy Product Info

😃Good

Hot

Synonyms: PD1-PDL1 inhibitor 2, PD-1/PD-L1 inhibitor 2

Catalog No. T3146 Copy Product Info

Purity: 99.66%

😃Good

Hot

BMS-202 (PD1-PDL1 inhibitor 2) is a non-peptide PD-1/PD-L complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 with high affinity and blocks human PD-1/PD-L interactions, exhibiting antitumor activity.

Cas No. 1675203-84-5

Pack Size	Price	USA Stock	Global Stock
1 mg	$41	In Stock	In Stock
5 mg	$102	In Stock	In Stock
10 mg	$163	In Stock	In Stock
25 mg	$323	In Stock	In Stock
50 mg	$538	In Stock	In Stock
100 mg	$633	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$108	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.66%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	BMS-202 (PD1-PDL1 inhibitor 2) is a non-peptide PD-1/PD-L complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 with high affinity and blocks human PD-1/PD-L interactions, exhibiting antitumor activity.
Targets & IC50	PD-1/PD-L1:0.018 μM
In vitro	Methods: HFB cell monolayers were treated with BMS-202 (0, 1, 2.5, 5 nM) for 24 hours, and scratch area measurements at 0h and 24h were compared. HFB monolayer cells were treated with BMS-202 (0, 1, 2.5, 5 nM) for 24 hours. After treatment, 0.5 μCi [³H]-proline was added, and incubation continued for 24 hours. Radioactive incorporation was then measured. Results: BMS-202 concentration-dependently inhibited HFB migration and collagen synthesis. [1] Methods: A375 melanoma cells were treated with BMS-202 (5 μM) or mitochondrial pyruvate carrier inhibitor GW604714X (10 μM) for 24 hours. Cell viability was assessed using the CCK-8 assay. Results: Combined treatment exhibited stronger cell viability suppression and apoptosis induction than either agent alone, indicating that mitochondrial dysfunction potentiates the antitumor effects of BMS-202. [2]
In vivo	Methods: A375 cells were subcutaneously implanted into nude mice to establish a melanoma xenograft model. Once tumors became palpable, BMS-202 (20 mg/kg) was administered via intraperitoneal injection every 3 days. Mice were euthanized on the third day after the third injection. Results: Tumor growth was significantly slowed in the BMS-202-treated group, with a marked reduction in the proportion of Ki-67-positive cells in tumor tissue, confirming an antiproliferative effect in vivo. [2]
Synonyms	PD1-PDL1 inhibitor 2, PD-1/PD-L1 inhibitor 2
Kinase Assay	All binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively).

Chemical Properties

Molecular Weight	419.52
Formula	C₂₅H₂₉N₃O₃
Cas No.	1675203-84-5
Smiles	COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O
Relative Density.	1.133 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 45 mg/mL (107.27 mM), Sonication is recommended.

Ethanol: 83 mg/mL (197.85 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.5 mg/mL (10.73 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/Ethanol

	1mg	5mg	10mg	50mg
1 mM	2.3837 mL	11.9184 mL	23.8368 mL	119.1838 mL
5 mM	0.4767 mL	2.3837 mL	4.7674 mL	23.8368 mL
10 mM	0.2384 mL	1.1918 mL	2.3837 mL	11.9184 mL
20 mM	0.1192 mL	0.5959 mL	1.1918 mL	5.9592 mL
50 mM	0.0477 mL	0.2384 mL	0.4767 mL	2.3837 mL
100 mM	0.0238 mL	0.1192 mL	0.2384 mL	1.1918 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.